Back to 2026 Abstracts
Innovative Use Of A Self-expanding Valve For Valve-in-valve Transcatheter Mitral Valve Replacement: 5 Years Follow Up
HAIBO ZHANG.
Beijing Anzhen Hospital, Tongzhou, Beijing, China, beijing, China.
BACKGROUND:Valve-in-valve transcatheter mitral valve replacement (ViV-TMVR) isa minimally invasive option for patients with bioprosthetic mitral valve failure. Since January 2019, our center has been using a new innovative option, J-Valve, to treat patients with bioprosthetic mitral valve failure who were at high risk for open heart surgery. The aim of this study is to explore the effectiveness and safety of J-Valve and report the results from the 5 year follow-up
METHODS:Patients who underwent the ViV-TMVR procedure between January2019 and September 2022 in our center were included. J-ValveTM system with three U-shape grippers was used for ViV-TMVR via transapical approach. Data on survival, complications, transthoracic echocardiographic results, New York Heart Association functional class in heart failure, and patient-reported health-related quality of life according to the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) were collected during the 5 year follow up
RESULTS:Thirty-three patients (mean age 70.1 ± 1.1 years, 13 men) were included and received ViV-TMVR. The surgery success rate was 97%: only one converted to open-heart surgery due to valve embolization. During the first 30 days all-cause mortality was 0%, risk of stroke 2.5% and risk of mild paravalvular leak 15.2%; mitral valve hemodynamics improved (179.7 ± 8.9 at 30 days vs. 269 ± 49 cm/s at baseline, p < 0.0001). During the 5years follow-up, all-cause mortality was 6.1%, and the risk of cerebral infarction 6.1%. Cox regression analysis did not identify any variables significantly associated with survival. The New York Heart Association functional class and the KCCQ-12 score improved significantly compared with their preoperative values.
CONCLUSIONS: The use of J-Valve for ViV-TMVR is safe and effective with a high success rate, low mortality and very few associated complications, representing an alternative surgical strategy for the elderly, high-risk patients with bioprostheticmitral valve failure.
Back to 2026 Abstracts
